NCT00420056 - An Investigational Study Drug, Palbociclib (PD-0332991), Is Being Studied In Patients With Mantle Cell Lymphoma. Patients Must Have Received Prior Treatment(s) For Mantle Cell Lymphoma. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2012

Conditions

Lymphoma, Mantle-Cell

Interventions

DRUG

PD-0332991

125 mg, oral, Days 1-21 of a 28-day cycle

Trial Locations (6)

Memorial Sloan-Kettering Cancer Center, New York

New York Presbyterian Hospital, New York

Weill Medical College of Cornell University - New York Presbyterian Hospital, New York

Fox Chase Cancer Center, Philadelphia

Brigham & Women's Hospital, Boston

Dana-Farber Cancer Institute, Boston